VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 10, 2007) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that an abstract, entitled "Anti cancer effect of a combination of CXCR4 antagonist CTCE-9908 and Docetaxel in a murine model of human prostate cancer", submitted by the Company has been accepted by the American Association for Cancer Research ("AACR") for presentation at the Molecular Targets and Cancer Therapeutics International Conference being held in San Francisco, California, October 22 - 26, 2007. The data will be presented by Dr. Donald Wong, Director of Pre-Clinical Drug Development for the Company.
